Bill > HB1292

This bill expands the Right to Try Act in New Hampshire to include patients with "qualifying severe illness" (defined as chronic and debilitating conditions) and introduces comprehensive regulations for regenerative stem cell therapies. The bill removes previous definitions of investigational treatments and broadens access to unapproved medical treatments for patients with terminal or severe illnesses. It establishes detailed requirements for stem cell therapies, including strict consent procedures, facility accreditation standards, and advertising disclosures. Physicians may now perform stem cell therapies for orthopedics, wound care, and pain management using stem cells from ethically sourced origins like placentas or consensual adult donors. The bill explicitly prohibits the use of stem cells derived from fetuses or embryos after an abortion, with violations subject to felony charges. The legislation aims to promote medical innovation while maintaining ethical standards, providing patients with more treatment options, and protecting healthcare providers who participate in these experimental treatments. The bill is set to take effect on January 1, 2027, and includes provisions for patient informed consent, physician liability protection, and regulatory oversight of experimental treatments.

Justice

https://gc.nh.gov/bill_Status/billinfo.aspx?id=2028&inflect=2